EGFR and lung cancer: In this study, we prospectively explored the role of ctDNA in detecting EGFR mutations in patients' plasma and determined the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with suspected advanced lung cancer, in the absence of pathologic diagnosis.